The vulnerability of IDH2 mutations to Ven‐HMA therapy makes a case for its upfront use; in a multicenter study of 151 patients ≥ 60 years with IDH1/2 mutated AML (90 IDH2 mutated), receiving Ven‐HMA or intensive chemotherapy, CR/CRi (67% vs. 67%) and overall survival rates (2 year survival; 49% vs. 38%) were similar after adjusting for baseline patient characteristics [18]. This evidence concerns the gene IDH1 and acute myeloid leukemia.